NEO - Why Is Cancer Genetics Test-Focused NeoGenomics Stock Trading Higher Today? | Benzinga
Tuesday, NeoGenomics Inc (NASDAQ:NEO) reported fourth-quarter 2023 adjusted EPS of $0.03, a turnaround from a loss of $(0.06), beating the consensus of $(0.02).
The company reported sales of $155.55 million, up 12.1% Y/Y, beating the consensus of $152.54 million.
Clinical Services revenue of $130 million increased 20% Y/Y. Clinical test volume increased by 6%. Average revenue per clinical test increased by 13% to $441.
Advanced Diagnostics revenue decreased by 17% to $25 million compared to the fourth quarter of 2022.
The adjusted gross profit margin reached 46.7%, up from 44.5% a year ago.